Immune Regulation and DynPort Vaccine Company partner to advance COVID-19 drug in clinical trials
Immune Regulation’s drug candidate IRL201104 has been shown to quickly and markedly reduce excessive infiltration of neutrophils…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.